

Cancer in Manitoba

2021 ANNUAL STATISTICAL REPORT



Department of Epidemiology & Cancer Registry

 CancerCare Manitoba
Action Cancer Manitoba

VISION

A world free of cancer

MISSION

To reduce and, where possible, eliminate the burden of cancer on the people of Manitoba through exemplary programs of prevention, diagnosis, treatment, rehabilitation, continuing care, research, and education.

REPORT OUTLINE

- 1.0. Report Overview
- 2.0. Facts & Figures: Manitoba's Cancer Profile
- 3.0. Cancer Incidence
 - 3.1. Incidence by Sex and Cancer Type
 - 3.2. Incidence by Age Group and Cancer Type
 - 3.3. Incidence by Geographic Area
 - 3.4. Incidence Trends – 4 Most Common Cancer Types
- 4.0. Cancer Stage Data
- 5.0. Cancer Mortality
 - 5.1. Mortality by Sex and Cancer Type
 - 5.2. Mortality Trends – 4 Most Common Cancer Types
- 6.0. Appendices
 - 6.1. Data Sources
 - 6.2. Population Data
 - 6.3. Supplementary Data
 - 6.4. Cancer Site Groupings ICD-O3
 - 6.5. Glossary and Definitions
 - 6.6. Citation and Referencing

1.0 REPORT OVERVIEW

The “**Cancer in Manitoba 2021 Annual Statistical Report**” provides a yearly update on cancer surveillance efforts in Manitoba. This report is for the general public, researchers, healthcare professionals, and decision-makers who require a simple understanding of the current provincial cancer burden, outcomes, and status.

This annual statistical report, analyzed by the **Department of Epidemiology, CancerCare Manitoba**, includes indicators of “**Cancer Incidence**”, “**Cancer Stage at Diagnosis**”, and “**Cancer Mortality**”. Data used to produce this report is provided by the **Manitoba Cancer Registry** and the **Vital Statistics Agency of Manitoba**.

1.1 Manitoba Cancer Registry

The Manitoba Cancer Registry is an essential tool for evidence-based, data-driven decision-making that immensely impacts cancer treatment and research. The Registry data is used for:

- healthcare planning and monitoring
- surveillance and studies on the causes and prevention of cancer, cancer clusters, treatment patterns, outcomes, and survival
- patient care
- quality assurance, and
- reporting to the Canadian Cancer Registry, the North American Association of Central Cancer Registries, and the International Association of Cancer Registries

The Manitoba Cancer Registry has collected cancer stage data for all cases of cancer (excluding non-melanoma skin cancer) diagnosed since January 1, 2004. From 2004 to 2017, collection followed the Collaborative Staging method consistent with the American Joint Committee on Cancer (AJCC) 6th and 7th Tumour, Nodes, and Metastases (TNM) editions. For cancer cases diagnosed on January 1, 2018, and forward, cancer stage data is being collected following the AJCC 8th edition of the TNM manual.

The Manitoba Cancer Registry uses disease site groupings according to the International Classification of Diseases for Oncology Third Edition (ICD-O3), based on Surveillance Epidemiology and End Results (SEER) Groups. See [Appendix](#) for the primary site groupings used for incidence.

NOTE: *All statistics in this report only include Manitoba residents.*

Additional statistical information is available upon request. Please contact the Manitoba Cancer Registry at 1-877-787-1272 (toll-free), or CCMBepireg@cancercare.mb.ca

2.0 FACTS & FIGURES: MANITOBA'S CANCER PROFILE

Cancer is a significant health issue. In 2021, **12,214** Manitobans were diagnosed with cancer:

- **7,307** invasive cancers
- **4,007** *in situ* (confined to the area of origin)
- **301** unspecified cancers
- **101** benign brain and CNS (central nervous system)

In this same year, **174.7 per 100,000** people died from invasive cancer.

The number of cancer cases in Manitoba is influenced by three factors:

- the age of the population
- the size of the population, and
- risk factors such as lifestyle factors (including smoking, poor diet, inactivity, sun exposure), some environmental carcinogens, genetic predisposition and not being screened

3.0 CANCER INCIDENCE

Cancer incidence refers to the number of new cases of a particular cancer type diagnosed in a population, during a specific time point or period.

Incident counts and rates are presented in this report for individuals diagnosed with cancer in Manitoba in the 2021 calendar year. Age-standardized incidence rates (ASIR) are presented per 100,000 population and allow comparisons between cancer rates in different regions of the province with different age structures. Rates are age-standardized (using the direct method) to the 2011 Manitoba population.

Data on cancer incidence is presented in this report by

- cancer type
- sex
- age group
- geographic area, and
- trends (4 most common cancer types)

3.1 INCIDENCE BY SEX AND CANCER TYPE

In 2021, the total number of Manitobans diagnosed with new cancers was **12,214** with an age-standardized incidence rate of **798.43** per 100,000. The age-standardized incidence rate for all cancers was higher in males (842.26 per 100,000) than in females (778.24 per 100,000) (**Table 1**).

In **Figure 1** and **Table 2**, we present the proportion of new invasive cancers diagnosed in Manitoba, in 2021, by sex for cancer types with 30 or more diagnoses.

The four most common cancers – breast, prostate, lung & bronchus, and colorectal - accounted for ~52% of the total invasive cancer diagnoses. In males, prostate cancer (26.23%), colorectal cancer (13.29%), and cancers of the lung & bronchus (11.56%) were the most commonly diagnosed; while breast cancer (28.13%), cancers of the lung & bronchus (13.40%), and colorectal cancer (11.37%) were the most commonly diagnosed in females.

Table 1: Cancer Incidence - New Case Counts and ASIRs by Sex and Cancer Type, Manitoba, 2021


CANCER TYPE	MALE		FEMALE		TOTAL	
	NEW CASES	ASIR	NEW CASES	ASIR	NEW CASES	ASIR
Lip	41	5.57	18	2.23	59	3.80
Tongue	49	6.80	8	1.06	57	3.78
Major salivary gland	5	0.71	13	1.71	18	1.21
Floor of mouth	6	0.76	7	0.84	13	0.80
Gum & other mouth	17	2.34	5	0.57	22	1.40
Nasopharynx	1	0.12	2	0.22	3	0.17
Oropharynx	11	1.61	2	0.28	13	0.90
Hypopharynx	5	0.59	2	0.24	7	0.42
Other buccal cavity & pharynx	35	4.83	4	0.50	39	2.62
Esophagus	62	8.39	20	2.31	82	5.28
Stomach	100	13.96	48	5.80	148	9.51
Small intestine	28	3.92	21	2.38	49	3.16
Colorectal	499	69.94	404	49.54	903	59.05
Colon excluding rectum	301	42.43	290	35.14	591	38.49
Rectum & rectosigmoid	198	27.51	114	14.40	312	20.56
Anus	9	1.19	27	3.43	36	2.42
Liver	50	6.54	32	3.86	82	5.16
Gallbladder	11	1.37	17	2.02	28	1.72
Pancreas	123	16.81	81	9.80	204	13.16

Other digestive system	42	5.93	45	5.26	87	5.62
Larynx	27	3.64	6	0.75	33	2.13
Lung & bronchus	434	59.40	476	56.63	910	57.69
Other respiratory system	14	2.16	5	0.66	19	1.32
Bones & joints	2	0.24	8	1.09	10	0.66
Soft tissue (Including heart)	28	4.03	33	4.41	61	4.14
Kaposi sarcoma	2	0.31	1	0.16	3	0.21
Mesothelioma	19	2.95	4	0.49	23	1.54
Melanoma of the skin	175	24.58	140	17.45	315	20.61
Breast	3	0.53	999	127.54	1002	66.70
Cervix uteri	n/a	n/a	60	8.28	60	8.28
Corpus uteri	n/a	n/a	279	35.62	279	35.62
Uterus, NOS	n/a	n/a	4	0.56	4	0.56
Ovary	n/a	n/a	93	12.25	93	12.25
Other female genital system	n/a	n/a	46	5.64	46	5.64
Prostate	985	130.96	n/a	n/a	985	130.96
Testis	30	4.34	n/a	n/a	30	4.34
Penis	8	1.20	n/a	n/a	8	1.20
Other male genital system	3	0.42	n/a	n/a	3	0.42
Bladder	128	18.28	40	4.77	168	10.82
Kidney	169	23.79	74	9.12	243	16.08
Ureter	6	0.78	2	0.24	8	0.49
Other urinary system	6	0.92	2	0.24	8	0.52
Eye	10	1.66	2	0.26	12	0.84
Brain	54	7.40	37	4.90	91	6.13
Other nervous system	0	0	0	0	0	0
Thyroid	55	7.77	114	15.92	169	11.81
Other endocrine	13	1.76	12	1.60	25	1.68
Hodgkin lymphoma	23	3.29	19	2.73	42	2.99
Non-Hodgkin lymphoma	178	25.45	137	16.81	315	20.61
Multiple myeloma	58	7.70	36	4.25	94	5.90
Acute lymphocytic leukemia	7	1.01	7	1.05	14	1.04
Chronic lymphocytic leukemia/Small lymphocytic lymphoma	45	6.12	28	3.57	73	4.76
Acute myeloid leukemia	41	5.73	31	3.90	72	4.71
Chronic myeloid leukemia	8	1.22	6	0.82	14	0.99
Other leukemias	9	1.30	3	0.38	12	0.81
Other ill-defined & unknown	121	17.72	92	11.06	213	13.98
TOTAL – INVASIVE	3755	518.05	3552	445.23	7307	475.44
Non-Melanoma skin	1522	214.32	1280	157.35	2802	182.33
<i>In situ</i> Skin	394	55.84	361	43.61	755	48.67
Breast <i>in situ</i>	0	0	132	17.31	132	8.85
Cervix <i>in situ</i>	0	0	481	69.02	481	69.02
Prostate <i>in situ</i>	17	2.21	0	0	17	2.21
Bladder <i>in situ</i>	141	19.97	39	4.65	180	11.59
Other <i>in situ</i> (Excl. Breast, Skin, Cervix, Prostate, Bladder)	45	5.94	93	12.19	138	9.07
TOTAL - INVASIVE + <i>IN SITU</i>	5874	816.33	5938	749.37	11812	771.33
Brain uncertain & unspecified	9	1.20	8	1.07	17	1.11
Neoplasms (Uncertain & unspecified, excluding brain)	137	19.36	147	19.21	284	18.99
Brain & nervous system benign	37	5.37	64	8.58	101	7.01
ALL CANCERS	6057	842.26	6157	778.24	12214	798.43

Notes:

- n/a – Not Applicable
- ASIR – Age-standardized Incidence Rate. Rates are per 100,000 persons and age-standardized to the 2011 Manitoba population

Figure 1: Proportion of New Invasive Cancer Cases by Sex and Cancer Type, Manitoba, 2021



Note: AML – Acute Myeloid Leukemia; CLL - Chronic Lymphocytic Leukemia; SLL - Small Lymphocytic Lymphoma.

- Cancer sites presented are for cancer types with 30 or more new cases. Cancer sites with less than 30 new cases are summed up as “Other cancer types”

Table 2: Proportion of New Invasive Cancer Cases by Sex, Manitoba, 2021

CANCER TYPE	MALE		FEMALE		TOTAL	
	Number	Percent	Number	Percent	Number	Percent
Breast	3	0.08	999	28.13	1002	13.71
Prostate	985	26.23	n/a	n/a	985	13.48
Lung & bronchus	434	11.56	476	13.4	910	12.45
Colorectal	499	13.29	404	11.37	903	12.36
Non-Hodgkin lymphoma	178	4.74	137	3.86	315	4.31
Melanoma of the skin	175	4.66	140	3.94	315	4.31
Corpus uteri	n/a	n/a	279	7.85	279	3.82
Kidney	169	4.5	74	2.08	243	3.33
Other ill-defined & unknown	121	3.22	92	2.59	213	2.92
Pancreas	123	3.28	81	2.28	204	2.79
Thyroid	55	1.46	114	3.21	169	2.31
Bladder	128	3.41	40	1.13	168	2.3
Stomach	100	2.66	48	1.35	148	2.03
Multiple myeloma	58	1.54	36	1.01	94	1.29
Ovary	n/a	n/a	93	2.62	93	1.27
Brain	54	1.44	37	1.04	91	1.25
Other digestive system	42	1.12	45	1.27	87	1.19
Esophagus	62	1.65	20	0.56	82	1.12
Liver	50	1.33	32	0.9	82	1.12
Chronic lymphocytic leukemia/Small lymphocytic lymphoma	45	1.2	28	0.79	73	1
Acute myeloid leukemia	41	1.09	31	0.87	72	0.99
Soft tissue (Including heart)	28	0.75	33	0.93	61	0.83
Cervix uteri	n/a	n/a	60	1.69	60	0.82
Lip	41	1.09	18	0.51	59	0.81
Tongue	49	1.3	8	0.23	57	0.78
Small intestine	28	0.75	21	0.59	49	0.67
Other female genital system	n/a	n/a	46	1.3	46	0.63
Hodgkin lymphoma	23	0.61	19	0.53	42	0.57
Other buccal cavity & pharynx	35	0.93	4	0.11	39	0.53
Anus	9	0.24	27	0.76	36	0.49
Larynx	27	0.72	6	0.17	33	0.45
Testis	30	0.8	n/a	n/a	30	0.41
Other cancer types	163	4.33	104	2.96	267	3.64

Note: n/a – Not Applicable.

- Cancer sites presented are for cancer types with 30 or more new cases. Cancer sites with less than 30 new cases are summed up as “Other cancer types”.

3.2 INCIDENCE BY AGE GROUP AND CANCER TYPE

The age distribution of newly diagnosed cancers in 2021 is shown in **Table 3**. Age-specific rates varied by cancer type and increased from 20.20 per 100,000 in people aged between 0 - 14 years to 4066.77 per 100,000 in people aged 80 and older. Most new cancer diagnoses were recorded in people between the ages of 70 and 79 years (n = 3546, rate = 3497.01 per 100,000).

Table 3: Incidence Counts and Rates by Cancer Type and Age Group, Manitoba, 2021


CANCER TYPE	AGES 0 - 14		AGES 15 - 39		AGES 40 - 59		AGES 60 - 69		AGES 70 - 79		AGES 80+	
	NEW CASES	AGE-SPECIFIC RATE	NEW CASES	AGE-SPECIFIC RATE	NEW CASES	AGE-SPECIFIC RATE	NEW CASES	AGE-SPECIFIC RATE	NEW CASES	AGE-SPECIFIC RATE	NEW CASES	AGE-SPECIFIC RATE
Lip	0	0	0	0	9	2.60	13	8.09	22	21.70	15	25.76
Tongue	0	0	1	0.21	16	4.62	20	12.45	13	12.82	7	12.02
Major salivary gland	0	0	0	0	6	1.73	7	4.36	3	2.96	2	3.43
Floor of mouth	0	0	0	0	2	0.58	7	4.36	4	3.94	0	0
Gum & other mouth	0	0	1	0.21	1	0.29	6	3.74	7	6.90	7	12.02
Nasopharynx	0	0	0	0	0	0	2	1.25	1	0.99	0	0
Oropharynx	0	0	0	0	5	1.44	4	2.49	2	1.97	2	3.43
Hypopharynx	0	0	0	0	0	0	3	1.87	3	2.96	1	1.72
Other buccal cavity & pharynx	0	0	1	0.21	15	4.33	14	8.72	8	7.89	1	1.72
Esophagus	0	0	0	0	16	4.62	25	15.57	27	26.63	14	24.04
Stomach	0	0	0	0	20	5.77	39	24.28	51	50.30	38	65.26
Small intestine	0	0	0	0	8	2.31	14	8.72	16	15.78	11	18.89
Colorectal	1	0.38	23	4.94	171	49.33	237	147.56	269	265.28	202	346.91
<i>Colon excluding rectum</i>	1	0.38	13	2.79	92	26.54	134	83.43	194	191.32	157	269.63
<i>Rectum & rectosigmoid</i>	0	0	10	2.15	79	22.79	103	64.13	75	73.96	45	77.28
Anus	0	0	0	0	10	2.88	10	6.23	8	7.89	8	13.74
Liver	1	0.38	0	0	12	3.46	36	22.41	24	23.67	9	15.46
Gallbladder	0	0	0	0	2	0.58	8	4.98	13	12.82	5	8.59
Pancreas	0	0	3	0.64	32	9.23	50	31.13	71	70.02	48	82.43
Other digestive system	1	0.38	1	0.21	9	2.60	28	17.43	24	23.67	24	41.22
Larynx	0	0	1	0.21	7	2.02	13	8.09	8	7.89	4	6.87
Lung & bronchus	0	0	7	1.50	108	31.16	258	160.64	337	332.34	200	343.48
Other respiratory system	0	0	4	0.86	4	1.15	3	1.87	2	1.97	6	10.30
Bones & joints	2	0.76	2	0.43	1	0.29	4	2.49	1	0.99	0	0
Soft tissue (Including heart)	3	1.14	7	1.50	16	4.62	9	5.60	16	15.78	10	17.17
Kaposi sarcoma	0	0	0	0	1	0.29	1	0.62	0	0	1	1.72
Mesothelioma	0	0	1	0.21	3	0.87	2	1.25	7	6.90	10	17.17
Melanoma of the skin	0	0	17	3.65	64	18.46	86	53.55	89	87.77	59	101.33
Breast	0	0	47	10.09	288	83.08	271	168.73	255	251.48	141	242.15
Cervix uteri	0	0	18	3.87	22	6.35	14	8.72	4	3.94	2	3.43
Corpus uteri	0	0	5	1.07	84	24.23	104	64.75	70	69.03	16	27.48
Uterus, NOS	0	0	0	0	2	0.58	2	1.25	0	0	0	0
Ovary	1	0.38	10	2.15	30	8.65	28	17.43	15	14.79	9	15.46
Other female genital system	0	0	1	0.21	9	2.60	13	8.09	16	15.78	7	12.02
Prostate	0	0	0	0	110	31.73	365	227.26	369	363.90	141	242.15
Testis	1	0.38	19	4.08	7	2.02	1	0.62	1	0.99	1	1.72
Penis	0	0	1	0.21	1	0.29	0	0	3	2.96	3	5.15
Other male genital system	0	0	0	0	0	0	1	0.62	1	0.99	1	1.72
Bladder	0	0	2	0.43	17	4.90	37	23.04	59	58.18	53	91.02
Kidney	2	0.76	10	2.15	67	19.33	76	47.32	59	58.18	29	49.80
Ureter	0	0	0	0	0	0	4	2.49	2	1.97	2	3.43
Other urinary system	0	0	0	0	0	0	5	3.11	0	0	3	5.15
Eye	1	0.38	0	0	2	0.58	1	0.62	2	1.97	6	10.30
Brain	11	4.19	11	2.36	21	6.06	20	12.45	23	22.68	5	8.59
Other nervous system	0	0	0	0	0	0	0	0	0	0	0	0
Thyroid	0	0	38	8.16	70	20.19	34	21.17	22	21.70	5	8.59
Other endocrine	3	1.14	4	0.86	7	2.02	5	3.11	6	5.92	0	0
Hodgkin lymphoma	3	1.14	22	4.72	9	2.60	4	2.49	3	2.96	1	1.72
Non-Hodgkin lymphoma	1	0.38	13	2.79	58	16.73	86	53.55	90	88.76	67	115.06
Multiple myeloma	0	0	0	0	13	3.75	35	21.79	33	32.54	13	22.33
Acute lymphocytic leukemia	6	2.29	2	0.43	4	1.15	1	0.62	1	0.99	0	0

CLL/SLL	0	0	0	0	16	4.62	26	16.19	19	18.74	12	20.61
Acute myeloid leukemia	7	2.67	5	1.07	6	1.73	18	11.21	20	19.72	16	27.48
Chronic myeloid leukemia	0	0	1	0.21	6	1.73	1	0.62	3	2.96	3	5.15
Other leukemias	0	0	1	0.21	3	0.87	2	1.25	3	2.96	3	5.15
Other ill-defined & unknown	0	0	7	1.50	26	7.50	46	28.64	62	61.14	72	123.65
TOTAL - INVASIVE	44	16.77	286	61.41	1416	408.48	2099	1306.90	2167	2137.06	1295	2224.02
Non-Melanoma skin	0	0	53	11.38	458	132.12	694	432.11	887	874.74	710	1219.34
<i>In situ</i> skin	0	0	16	3.44	85	24.52	169	105.22	262	258.38	223	382.98
Breast <i>in situ</i>	0	0	1	0.21	50	14.42	45	28.02	30	29.59	6	10.30
Cervix <i>in situ</i>	0	0	354	76.02	102	29.42	21	13.08	4	3.94	0	0
Prostate <i>in situ</i>	0	0	0	0	3	0.87	7	4.36	6	5.92	1	1.72
Bladder <i>in situ</i>	0	0	1	0.21	27	7.79	43	26.77	65	64.10	44	75.57
Other <i>in situ</i> (Excl. Breast, Skin, Cervix, Prostate, Bladder)	0	0	11	2.36	35	10.10	38	23.66	39	38.46	15	25.76
TOTAL - INVASIVE + <i>IN SITU</i>	44	16.77	722	155.04	2176	627.72	3116	1940.12	3460	3412.20	2294	3939.69
Brain uncertain & unspecified	0	0	7	1.50	2	0.58	3	1.87	4	3.94	1	1.72
Neoplasms (Uncertain & unspecified, excl. brain)	9	3.43	39	8.37	59	17.02	62	38.60	69	68.05	46	79.00
Brain & nervous system benign	0	0	12	2.58	27	7.79	22	13.70	13	12.82	27	46.37
ALL CANCERS	53	20.20	780	167.49	2264	653.10	3203	1994.28	3546	3497.01	2368	4066.77

Note: Rates are per 100,000 persons

- CLL/SLL: Chronic lymphocytic leukemia/Small lymphocytic lymphoma

Distribution of New Cancer Cases by Age Group, Manitoba 2021



Age 0 to 14

For the 0 to 14 year age group, in 2021, a total of 53 new cancers (rate = 20.20 per 100,000) were diagnosed. Brain cancers (11 diagnoses, rate = 4.19 per 100,000) were the most common diagnosis in this age group.

Age 15 to 39

There were 780 (rate = 167.49 per 100,000) new diagnoses in 2021 among those aged 15 to 39. The majority were *in situ* cervical cancer (354 cases; rate = 76.02 per 100,000) diagnoses, with the most common invasive diagnosis being that of breast cancer (47 diagnoses; rate = 10.09).

Age 40 to 59

In 2021, 2264 new cancer cases (rate = 653.10 per 100,000) were diagnosed in the 40 to 59 year age group. Of all the new cancer diagnoses in this age group, the most commonly diagnosed invasive cancers were:

- breast (n = 288, rate = 83.08 per 100,000),
- colorectal (n = 171, rate = 49.33 per 100,000),
- prostate (n = 110, rate = 31.73 per 100,000), and
- lung and bronchus (n = 108, rate = 31.16 per 100,000).

Non-melanoma skin cancer was also commonly diagnosed in this age group (458 diagnoses; rate = 132.12 per 100,000)

Age 60 to 69

A total of 3203 cancer cases (rate = 1994.28 per 100,000) were diagnosed in Manitoba, in 2021, among people in the 60 to 69 year age group. The most common cancers were:

- colorectal (n = 237, rate = 147.56 per 100,000)
- lung & bronchus (n = 258, rate = 160.64 per 100,000)
- breast (n = 271, rate = 168.76 per 100,000) and
- prostate (n = 365, rate = 227.26 per 100,000)

Age 70 to 79

For people in the 70 to 79 year age group, the number of new cancer diagnoses in 2021 was 3546 (rate = 3497.01 per 100,000). The most common invasive cancers were:

- colorectal (n = 269, rate = 265.28 per 100,000)
- lung & bronchus (n = 337, rate = 332.34 per 100,000)
- breast (n = 255, rate = 251.48 per 100,000) and
- prostate (n = 369, rate = 363.90 per 100,000)

Age 80 and older

The highest cancer incidence rate (4066.77 per 100,000) in 2021 occurred in this age group with a total of 2368 new cases diagnosed. The most common diagnoses were:

- colorectal (n = 202, rate = 346.91 per 100,000)
- lung & bronchus (n = 200, rate = 343.48 per 100,000)
- breast (n = 141, rate = 242.15 per 100,000) and
- prostate (n = 141, rate = 242.15 per 100,000)

3.3 INCIDENCE BY GEOGRAPHIC AREA

3.3.1 Incidence by Manitoba Regional Health Authority (RHA)

There are five Regional Health Authorities (RHA) in Manitoba: Southern Health-Santé Sud, Prairie Mountain Health, the Northern Health Region, the Winnipeg Regional Health Authority (includes Churchill), and Interlake-Eastern. The rates and number of new invasive cancer cases diagnosed in Manitoba, in 2021, by RHA are reported in **Table 4** and **Figure 2** for both males and females.




Figure 2: Age-Standardized Incidence Rates of Invasive Cancers, Regional Health Authority, Manitoba 2021

Overall, Interlake-Eastern RHA had the highest rate (526.94 per 100,000) of new invasive cancer cases, with the lowest rate (448.25 per 100,000) recorded in Southern Health-Santé Sud. Despite being the most populous RHA in Manitoba, the Winnipeg RHA recorded the second-highest rate of invasive cancers in males (517.90 per 100,000) and ranked fourth highest in females (441.99 per 100,000)

Table 4: Incidence of Invasive Cancer by Manitoba Regional Health Authorities, 2021

RHA	POPULATION	MALE		FEMALE		TOTAL	
		INCIDENCE	ASIR	INCIDENCE	ASIR	INCIDENCE	ASIR
Southern Health-Santé Sud	215871	488	478.56	452	425.14	940	448.45
Prairie Mountain Health	173393	512	494.56	504	460.05	1016	474.73
Northern Health Region	76955	135	514.23	121	463.67	256	487.16
Winnipeg Regional Health Authority	793365	2111	517.90	2073	441.99	4184	471.26
Interlake Eastern	135465	509	591.49	402	468.98	911	526.94

Note: ASIR – Age-standardized Incidence Rates. Rates are per 100,000 persons

3.3.2 Incidence by Manitoba RHA Zones

The incidence and ASIR for the 18 RHA zones in Manitoba, 2021, are presented in Table 5 and Figure 3




Figure 3: Age-Standardized Incidence Rates of Invasive Cancers, Manitoba RHA Zones, 2021

Table 5: Incidence of Invasive Cancer by Manitoba RHA Zones, 2021

RHA ZONES	POPULATION	INCIDENCE	ASIR
IE1 Interlake-Eastern Selkirk Zone	10541	89	601.43
IE2 Interlake-Eastern South Zone	62782	402	524.23
IE3 Interlake-Eastern East Zone	21113	157	468.54
IE4 Interlake-Eastern West Zone	15766	135	524.56
IE5 Interlake-Eastern North Zone	21008	115	574.10
IE6 Interlake-Eastern Northern Remote Zone	4255	13	718.92
NO1 Northern Direct Service Zone	37173	175	522.17
NO2 Northern Non-Direct Service Zone	30589	62	410.59
NO3 Northern Island Lake Zone	9193	19	642.77
SO1 Southern North Zone	44131	187	403.55
SO2 Southern Mid Zone	32395	181	512.42
SO3 Southern West Zone	56183	237	440.42
SO4 Southern East Zone	83162	335	449.14
WE1 PMH North Zone	41111	245	418.86
WE2 PMH Brandon Zone	55180	300	503.75
WE3 PMH South Zone	77102	471	485.31
WP1 Winnipeg Zone	792456	4181	471.37
WP2 Churchill Zone	909	3	324.70

Note: ASIR – Age-standardized Incidence Rates. Rates are per 100,000 persons

3.3.3 Incidence by Winnipeg Community Areas

Winnipeg is the capital and the most populous city in Manitoba. There are 12 community areas in Winnipeg and the incidence rates and counts for invasive cancers in 2021 are reported in **Table 6** and **Figure 4**.




Figure 4: Age-Standardized Incidence Rates of Invasive Cancers, Winnipeg Community Areas, 2021

Table 6: Incidence of Invasive Cancer by Winnipeg Community Areas, Manitoba, 2021

WINNIPEG COMMUNITY AREAS	POPULATION	INCIDENCE	ASIR
Assiniboine South	37916	245	462.22
Downtown	77029	326	424.35
Fort Garry	101123	460	435.72
Inkster	38774	139	386.40
Point Douglas	47441	211	512.51
River East	102996	621	498.01
River Heights	56694	321	471.12
Seven Oaks	84881	409	450.10
St. Boniface	66630	342	454.60
St. James Assiniboia	61426	435	539.01
St. Vital	72775	420	457.36
Transcona	44608	252	556.53

Note: ASIR – Age-standardized Incidence Rates. Rates are per 100,000 persons

3.4 INCIDENCE TRENDS – 4 MOST COMMON CANCER TYPES

Trends in counts, age-standardized incidence rates, and annual percentage changes in ASIRs from 2001 to 2021 for the 4 most common cancer diagnoses in Manitoba (breast, colorectal, lung & bronchus, and prostate) are shown in **Table 7** and **Figures 5 to 7**.

BREAST CANCER

The age-standardized incidence rate for female breast cancer in Manitoba increased by 0.2% per year from 2001 until 2011. It then decreased significantly by 3.76% annually from 2011 to 2015 before increasing significantly at 5.14% per year until 2018. However, in recent years from 2018 to 2021, there has been a significant decrease of 2.87% in the ASIR of breast cancer in Manitoba.

COLORECTAL CANCER

The age-standardized incidence rate for colorectal cancer increased by 0.6% per year from 2001 to 2009 while a significant decrease of 2.36% has been recorded annually from 2009 to 2021.

LUNG CANCER

From 2001 to 2021, the age-standardized incidence rate of lung cancer cases diagnosed in Manitoba has been decreasing significantly annually by 1.34%.

PROSTATE CANCER

There was a trend of significant decrease in the age-standardized incidence rate of prostate cancer by 3.03% in Manitoba from 2001 to 2014. However, recent years from 2014 to 2021 have seen a significant annual increase of 2.73% in rates of prostate cancer.




Figure 6: Trends of Age-standardized Incidence Rates of Top 4 Most Common Cancers, Manitoba, 2001 - 2021




Figure 7: Annual Percentage Change of Age-standardized Incidence Rates - Top 4 Cancer Types, Manitoba, 2001-2021




Table 7: Count, Incidence Rates, and Annual Percentage Changes of Top 4 Most Common Cancer Types, Manitoba 2001 – 2021

YEAR	COLORECTAL			LUNG & BRONCHUS			BREAST			PROSTATE		
	Counts	ASIR	APC (%)	Counts	ASIR	APC (%)	Counts	ASIR	APC (%)	Counts	ASIR	APC (%)
2001	745	69.77	0.599	801	75.73	-1.3424*	765	133.97	0.202	792	169.62	-3.0334*
2002	813	75.25	0.599	856	80.30	-1.3424*	771	135.71	0.202	740	160.09	-3.0334*
2003	739	67.44	0.599	842	76.86	-1.3424*	756	131.04	0.202	698	147.04	-3.0334*
2004	795	71.28	0.599	861	78.06	-1.3424*	803	135.14	0.202	734	151.71	-3.0334*
2005	761	67.16	0.599	885	78.84	-1.3424*	792	132.49	0.202	616	125.97	-3.0334*
2006	797	69.70	0.599	832	73.72	-1.3424*	813	134.14	0.202	703	139.74	-3.0334*
2007	856	73.63	0.599	857	74.25	-1.3424*	813	132.56	0.202	754	145.99	-3.0334*
2008	864	73.05	0.599	899	76.22	-1.3424*	839	133.69	0.202	645	121.44	-3.0334*
2009	911	75.69	---	919	76.41	-1.3424*	860	134.69	0.202	745	136.52	-3.0334*
2010	896	73.03	-2.3601*	886	72.31	-1.3424*	851	131.79	0.202	752	135.21	-3.0334*
2011	933	74.67	-2.3601*	884	70.73	-1.3424*	926	140.68	---	692	121.81	-3.0334*
2012	812	63.74	-2.3601*	876	68.63	-1.3424*	883	131.33	-3.7627*	643	108.60	-3.0334*
2013	835	64.23	-2.3601*	893	68.42	-1.3424*	857	125.64	-3.7627*	642	106.65	-3.0334*
2014	829	62.80	-2.3601*	982	73.40	-1.3424*	823	118.97	-3.7627*	713	115.16	---
2015	835	62.11	-2.3601*	950	69.61	-1.3424*	836	118.47	---	719	113.87	2.7320*
2016	856	61.99	-2.3601*	869	62.50	-1.3424*	882	123.24	5.1410*	742	113.95	2.7320*
2017	826	59.02	-2.3601*	910	63.88	-1.3424*	898	123.38	5.1410*	735	111.23	2.7320*
2018	884	62.13	-2.3601*	949	64.83	-1.3424*	1028	138.98	---	803	116.86	2.7320*
2019	853	58.42	-2.3601*	984	65.39	-1.3424*	1011	133.42	-2.8669*	956	136.30	2.7320*
2020	759	50.99	-2.3601*	963	62.09	-1.3424*	912	120.49	-2.8669*	925	127.49	2.7320*
2021	903	59.05	-2.3601*	910	57.69	-1.3424*	999	127.54	-2.8669*	985	130.96	2.7320*

Note:

- ASIR – Age-standardized Incidence Rates. Rates are per 100,000 persons
- APC – Annual Percentage Change; * - Significant difference


4.0 CANCER STAGE AT DIAGNOSIS

Cancer stage provides important information to help guide management and treatment decisions for individuals diagnosed with cancer. It is a means of classifying how a tumor grows and spreads in someone's body.

Stage 0 represents the earliest point of growth and spread of a cancer, and as the cancer progresses and spreads to other parts of the body, the cancer stage increases i.e. Stage I, II, or III; with stage IV (metastatic or late) representing the latest point of growth and spread.

Due to changes in the staging system, for this report, cancer stage data is presented as early/intermediate stage and late stage. Stage data in this report is shown for disease site groups with 45 or more diagnoses per year (**Table 8 & Figure 8**).

The distribution of stage at diagnosis varied by cancer type, with most individuals diagnosed at an early/intermediate stage. For some cancer types (pancreatic, and lung cancer) the majority of people are diagnosed at a late stage. Of the four most common cancer types, breast cancer had the highest proportion of individuals diagnosed at an early/intermediate stage – 94.2%; prostate cancer – 80.5%; colorectal cancer – 79.8%; with lung cancer diagnoses being the least (56.5% of early/intermediate stage at diagnosis).



Note:

- CLL/SLL: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Early/Intermediate includes non-metastatic and unknown-stage cancer diagnoses, while Late stage includes metastatic cancer diagnoses.
- In keeping with international coding conventions, all invasive brain tumors, multiple myeloma, and non-CLL leukemia are considered unstageable using the AJCC TNM 8th edition staging system utilized by all population-based North American Cancer Registries
- Cancer types with 30 or more cases are presented while cancer types with less than 30 cases are summed up and presented as "Other Cancer Types"

Table 8: Stage at Diagnosis by Invasive Cancer Type, Manitoba, 2021

CANCER TYPE	INCIDENCE	EARLY/INTERMEDIATE STAGE		LATE STAGE	
		Frequency	Percentage	Frequency	Percentage
Breast	1002	944	94.2%	58	5.8%
Prostate	985	793	80.5%	192	19.5%
Lung & bronchus	910	514	56.5%	396	43.5%
Colorectal	903	721	79.8%	182	20.2%
Melanoma of the skin	315	306	97.1%	9	2.9%
Non-Hodgkin lymphoma	315	166	52.7%	149	47.3%
Corpus uteri	279	270	96.8%	9	3.2%
Kidney	243	199	81.9%	44	18.1%
Pancreas	204	88	43.1%	116	56.9%
Thyroid	169	160	94.7%	9	5.3%
Bladder	168	143	85.1%	25	14.9%
Stomach	148	95	64.2%	53	35.8%
Ovary	93	80	86.0%	13	14.0%
Other digestive system	87	66	75.9%	21	24.1%
Esophagus	82	48	58.5%	34	41.5%
Liver	82	66	80.5%	16	19.5%
Chronic lymphocytic leukemia/Small lymphocytic lymphoma	73	62	84.9%	11	15.1%
Soft tissue (Including heart)	61	55	90.2%	6	9.8%
Cervix uteri	60	50	83.3%	10	16.7%
Lip	59	58	98.3%	1	1.7%
Tongue	57	37	64.9%	20	35.1%
Small intestine	49	40	81.6%	9	18.4%
Other female genital system	46	44	95.7%	2	4.3%
Hodgkin lymphoma	42	27	64.29%	15	35.71%
Other buccal cavity & pharynx	39	37	94.87%	2	5.13%
Anus	36	35	97.22%	1	2.78%
Larynx	33	23	69.70%	10	30.30%
Testis	30	30	100%	0	0%
Other cancer types	227	167	73.56%	60	26.43%

NOTE:

- Early/Intermediate includes non-metastatic and unknown-stage cancer diagnoses, while Late stage includes metastatic cancer diagnoses.
- In keeping with international coding conventions, all invasive brain tumors, multiple myeloma, and non-CLL leukemia are considered unstageable using the AJCC TNM 8th edition staging system utilized by all population-based North American Cancer Registries
- Cancer types with more than 30 cases are presented while cancer types with 30 cases or lower are summed up and presented as "Other Cancer Types"

5.0 CANCER MORTALITY

Mortality information refers to Manitobans who died of cancer in the 2021 calendar year. However, those individuals may not have been diagnosed in 2021. The leading cause of death in Manitoba in 2021 was Cancer (**Figure 9 and Table 9**).

Figure 9: Top 10 Leading Causes of Death, Manitoba, 2021




Table 9: Leading Causes of Deaths in Manitoba, 2021

LEADING CAUSES OF DEATH (ICD-10)	MALE			FEMALE			TOTAL		
	RANK	COUNT	ASMR	RANK	COUNT	ASMR	RANK	COUNT	ASMR
Malignant neoplasms [C00-C97]	1	1,435	214.1	1	1,169	144.6	1	2,604	174.7
<i>In situ neoplasms, benign neoplasms, and neoplasms of uncertain or unknown behaviour [D00-D48]</i>	14	39	6.2	15	31	3.4	14	70	4.5
Diseases of the heart [I00-I09, I11, I13, I20-I51]	2	1,195	185.3	2	843	91.2	2	2,038	133.7
Accidents [V01-X59, Y85-Y86]	3	381	58	5	250	30.1	3	631	44
COVID-19 [U07.1, U07.2, U10.9]	4	337	50.5	4	263	31.5	4	600	40.4
Cerebrovascular diseases [I60-I69]	5	187	29.4	3	272	29.1	5	459	29.8
Chronic lower respiratory diseases [J40-J47]	7	163	24.7	6	165	18.4	6	328	21.1
Diabetes mellitus [E10-E14]	6	168	25.9	7	141	17.5	7	309	21.1
Intentional self-harm (suicide) [X60-X84, Y87.0]	8	104	15.4	10	56	8.1	8	160	11.7
Chronic liver disease and cirrhosis [K70, K73-K74]	9	89	13.2	9	70	10.3	9	159	11.7
Nephritis, nephrotic syndrome, and nephrosis [N00-N07, N17-N19, N25-N27]	10	79	12.2	8	77	8	10	156	9.8

Note:

- ASMR – Age-standardized Mortality Rates. Rates are per 100,000 persons and standardized using the 2011 Canadian standard population
- Source: Statistics Canada. [Table 13-10-0801-01 Leading causes of death, total population \(age standardization using 2011 population\)](#)

5.1 MORTALITY BY SEX AND CANCER TYPES

In 2021, there were **2,604** deaths from invasive cancer (age-standardized mortality rate, ASMR: 174.7 per 100,000) and **70** deaths from non-invasive cancer (ASMR: 4.5 per 100,000) in Manitoba. The age-standardized mortality rate for invasive cancer was higher in males (214.1 per 100,000) than in females (144.6 per 100,000) (**Table 9**). Table 10 presents data on cancer deaths that occurred in Manitoba, in 2021, by sex and site.

The four most common cancer deaths among Manitobans in 2021 were from cancers of the

- Trachea, Bronchus, and Lung (n = 599; rate = 39.6 per 100,000)
- Colon, Rectum, and Anus (n = 300; rate = 20.5 per 100,000),
- Prostate (n = 191; rate = 12.5 per 100,000), and
- Pancreas (n = rate = 11.2 per 100,000)

In males, most cancer deaths were from cancer of the trachea, bronchus, and lung cancer (20.1%), prostate (13.3%), colon, rectum, and anus (11.8%), and pancreas (6.1%). Similarly, cancer of the trachea, bronchus, and lung cancer accounted for 26.5% of cancer deaths in females, followed by breast cancer (13.2%), colon, rectum, and anus (11.2%), and pancreas (6.8%).

Table 10: Cancer Death Counts and Mortality Rates by Sex and Cancer Type, 2021

CAUSE OF DEATH/CANCER TYPE	MALE		FEMALE		TOTAL	
	COUNT	ASMR	COUNT	ASMR	COUNT	ASMR
Lip, oral cavity, and pharynx	39	5.8	13	1.6	52	3.6
Esophagus	61	8.9	22	2.8	83	5.6
Stomach	50	7.5	20	2.6	70	4.8
Colon, rectum, and anus	169	25.5	131	16.1	300	20.5
Liver and intrahepatic bile ducts	57	7.9	33	4.2	90	6
Pancreas	87	13	79	9.7	166	11.2
Larynx	9	1.4	0	0	9	0.6
Trachea, bronchus, and lung	289	42	310	37.9	599	39.6
Melanoma of skin	22	3.2	13	1.7	35	2.4
Breast	0	0	154	20.2	154	10.8
Cervix uteri	n/a	n/a	13	1.7	13	0.9
Corpus uteri and uterus, part unspecified	n/a	n/a	50	5.9	50	3.2
Ovary	n/a	n/a	49	6.6	49	3.5
Prostate	191	29.8	n/a	n/a	191	12.5
Kidney and renal pelvis	44	6.4	19	2.2	63	4.1
Bladder	63	9.9	17	2.1	80	5.5
Meninges, brain, and other parts of central nervous system	36	5.1	18	2.4	54	3.7
Hodgkin lymphoma	1	0.2	1	0.1	2	0.2
Non-Hodgkin lymphoma	60	8.9	30	3.4	90	6
Leukaemia	57	8.6	42	5.1	99	6.5
Multiple myeloma and immunoproliferative neoplasms	32	4.6	16	1.9	48	3.2
Other/unspecified malignant neoplasms of lymphoid, haematopoietic, and related tissue	0	0	1	0.1	1	0.1
All other and unspecified malignant neoplasms	168	25.5	138	16.4	306	20.4
TOTAL - INVASIVE CANCERS	1,435	214.1	1,169	144.6	2,604	174.7
In situ neoplasms, benign neoplasms, and neoplasms of uncertain or unknown behaviour	39	6.2	31	3.4	70	4.5

Note:

- ASMR – Age-standardized Mortality Rates. Rates are per 100,000 persons
- n/a – Not Applicable
- Source: Statistics Canada. [Table 13-10-0800-01 Deaths and mortality rate \(age standardization using 2011 Canadian population\), by selected grouped causes](#)

5.2 MORTALITY TRENDS – MOST COMMON CANCER TYPES

The trend of number of deaths and age-standardized mortality rates for the 4 most common cancer types (breast, colorectal, lung & bronchus, and prostate) from 2001 to 2021 in Manitoba are shown in **Table 11** and **Figures 10 and 11**.

Figure 10: Trends of Cancer Deaths - Most Common Cancer Types, Manitoba 2001 - 2021




Figure 11: Trends of Age-standardized Mortality Rates of Top 4 Most Common cancer Types, Manitoba 2001 - 2021




Table 11: Death Counts and Mortality Rates of Top 4 Most Common Cancer Types, Manitoba 2001 – 2021

YEAR	TRACHEA, BRONCHUS, & LUNG		COLON, RECTUM, AND ANUS		BREAST		PROSTATE	
	COUNT	ASMR	COUNT	ASMR	COUNT	ASMR	COUNT	ASMR
2001	605	60.2	266	25.5	181	17.6	173	15.6
2002	604	58.3	331	31	200	19.3	168	14.9
2003	619	58.3	268	24.7	223	21	173	15.1
2004	661	61.6	306	27.6	228	21.2	183	15.7
2005	668	61.3	276	24.6	190	17	187	15.8
2006	668	61.6	266	23.3	211	18.5	139	11.7
2007	589	52.4	311	26.7	197	17	189	15.4
2008	629	54.4	299	25.6	206	17.7	177	14.3
2009	702	59.7	308	25.5	192	16.2	169	13.4
2010	681	56.9	308	25.2	195	15.7	180	14
2011	661	54.1	301	24	194	15.6	150	11.5
2012	620	50.5	293	23.4	175	14	162	12.6
2013	629	50.3	307	23.9	188	14.8	161	12.2
2014	714	56	359	27.5	191	15	194	14.5
2015	693	53	306	23.2	195	14.6	170	12.4
2016	664	49.9	309	22.8	210	15.7	182	13.3
2017	640	47.4	331	24.1	189	14.1	186	13.1
2018	606	43.8	3141	22.3	168	12.3	177	12.4
2019	687	48.2	342	23.9	198	14.4	198	13.5
2020	603	41.5	311	21.5	166	11.8	198	13.4
2021	599	39.6	300	20.5	154	10.8	191	12.5

Note:

- ASMR – Age-standardized Mortality Rates. Rates are per 100,000 persons
- n/a – Not Applicable
- Sources: Statistics Canada. [Table 13-10-0800-01 Deaths and mortality rate \(age standardization using 2011 Canadian population\), by selected grouped causes](#)

6.0 APPENDICES

6.1 Data Sources

Data for this report is obtained from the Manitoba Cancer Registry, the Vital Statistics Agency of Manitoba, and the Canadian Vital Statistics - Birth Database (CVSB) and Death Database (CVSD), Statistics Canada.

Data sources used to populate the Manitoba Cancer Registry include:

- provincial cytology and pathology departments
- admission/separation data from the provincial hospital abstracting system
- Manitoba Provincial Client Registry
- letters and “Report of Malignant Neoplasm Forms” from physicians and other health care providers
- hospital health records
- correspondence from other provincial and territorial cancer registries on Manitoba residents diagnosed and/or treated in those jurisdictions

6.2 Population Data

Data used in this report are based on Manitoba estimates provided by Manitoba Health and Statistics Canada. The standard population used for age standardization of incidence in this report is the 2011 Manitoba population (Table A.1), based on the 2011 Statistics Canada census.

Table A.1. Manitoba Standard Population, 2011, by Age Group

Age group	Standard population	Weights
00-29	498594	0.399446
30-39	160499	0.128583
40-49	174421	0.139736
50-59	172359	0.138084
60-69	119616	0.09583
70-79	69678	0.055822
80+	53047	0.042498
	1,248,241	

Table A.2. Canadian Standard Population, 2011, by Age Group

Age group	Standard population	Weights
00-29	12590808	0.366622
30-39	4601042	0.133974
40-49	5105827	0.148673
50-59	5044350	0.146883
60-69	3583383	0.104341
70-79	2073160	0.060366
80+	1344210	0.039141

Table A.3. W.H.O Standard Population, 2000-2025, by Age Group

Age group	Standard population	Weights
00-29	507522	0.50770
30-39	147548	0.14760
40-49	126256	0.12630
50-59	99165	0.09920
60-69	66777	0.06680
70-79	37287	0.03730
80+	15445	0.01545

6.3 Supplementary Data

Table A.4. Cancer Incidence - New Case Counts and ASIRs by Sex, Age Group, and Cancer Type, standardized using the 2011 Manitoba standard population

CANCER TYPE	AGE GROUP																					TOTAL			ASIR		
	00-29			30-39			40-49			50-59			60-69			70-79			80+			M	F	T	M	F	T
	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T
Lip	0	0	0	0	0	0	1	1	2	5	2	7	9	4	13	19	3	22	7	8	15	41	18	59	5.57	2.23	3.80
Tongue	1	0	1	0	0	0	4	1	5	9	2	11	17	3	20	12	1	13	6	1	7	49	8	57	6.80	1.06	3.78
Major salivary gland	0	0	0	0	0	0	0	3	3	1	2	3	3	4	7	0	3	3	1	1	2	5	13	18	0.71	1.71	1.21
Floor of mouth	0	0	0	0	0	0	0	0	0	1	1	2	3	4	7	2	2	4	0	0	0	6	7	13	0.76	0.84	0.80
Gum & other mouth	0	0	0	1	0	1	0	0	0	1	0	1	6	0	6	5	2	7	4	3	7	17	5	22	2.34	0.57	1.40
Nasopharynx	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	1	1	0	0	0	1	2	3	0.12	0.22	0.17
Oropharynx	0	0	0	0	0	0	1	0	1	3	1	4	3	1	4	2	0	2	2	0	2	11	2	13	1.61	0.28	0.90
Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	2	1	3	3	0	3	0	1	1	5	2	7	0.59	0.24	0.42
Other buccal cavity & pharynx	0	0	0	1	0	1	4	0	4	10	1	11	12	2	14	7	1	8	1	0	1	35	4	39	4.83	0.50	2.62
Esophagus	0	0	0	0	0	0	5	0	5	10	1	11	22	3	25	19	8	27	6	8	14	62	20	82	8.39	2.31	5.28
Stomach	0	0	0	0	0	0	2	4	6	12	2	14	23	16	39	40	11	51	23	15	38	100	48	148	13.96	5.80	9.51
Small intestine	0	0	0	0	0	0	2	0	2	6	0	6	8	6	14	8	8	16	4	7	11	28	21	49	3.92	2.38	3.16
Colorectal	5	3	8	9	7	16	23	22	45	76	50	126	140	97	237	151	118	269	95	107	202	499	404	903	69.94	49.54	59.05
<i>Colon excluding rectum</i>	4	3	7	5	2	7	10	13	23	39	30	69	71	63	134	104	90	194	68	89	157	301	290	591	42.43	35.14	38.49
<i>Rectum & rectosigmoid</i>	1	0	1	4	5	9	13	9	22	37	20	57	69	34	103	47	28	75	27	18	45	198	114	312	27.51	14.40	20.56
Anus	0	0	0	0	0	0	0	2	2	3	5	8	3	7	10	3	5	8	0	8	8	9	27	36	1.19	3.43	2.42
Liver	1	0	1	0	0	0	2	1	3	5	4	9	24	12	36	14	10	24	4	5	9	50	32	82	6.54	3.86	5.16
Gallbladder	0	0	0	0	0	0	0	1	1	0	1	1	3	5	8	7	6	13	1	4	5	11	17	28	1.37	2.02	1.72
Pancreas	0	0	0	3	0	3	3	1	4	18	10	28	29	21	50	50	21	71	20	28	48	123	81	204	16.81	9.80	13.16
Other digestive system	0	2	2	0	0	0	1	0	1	7	1	8	15	13	28	10	14	24	9	15	24	42	45	87	5.93	5.26	5.62
Larynx	0	0	0	1	0	1	0	1	1	5	1	6	13	0	13	5	3	8	3	1	4	27	6	33	3.64	0.75	2.13
Lung & bronchus	1	2	3	3	1	4	3	6	9	49	50	99	118	140	258	174	163	337	86	114	200	434	476	910	59.40	56.63	57.69
Other respiratory system	1	0	1	1	2	3	3	1	4	0	0	0	2	1	3	2	0	2	5	1	6	14	5	19	2.16	0.66	1.32
Bones & joints	0	3	3	0	1	1	0	0	0	0	1	1	2	2	4	0	1	1	0	0	0	2	8	10	0.24	1.09	0.66
Soft tissue (Including heart)	1	5	6	3	1	4	4	3	7	2	7	9	4	5	9	8	8	16	6	4	10	28	33	61	4.03	4.41	4.14
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0	1	0	1	2	1	3	0.31	0.16	0.21
Mesothelioma	0	0	0	1	0	1	0	0	0	2	1	3	2	0	2	5	2	7	9	1	10	19	4	23	2.95	0.49	1.54
Melanoma of the skin	1	2	3	6	8	14	11	13	24	23	17	40	52	34	86	48	41	89	34	25	59	175	140	315	24.58	17.45	20.61
Breast	0	4	4	0	43	43	0	104	104	1	183	184	0	271	271	0	255	255	2	139	141	3	999	1002	0.53	127.54	66.70
Cervix uteri	0	4	4	0	14	14	0	15	15	0	7	7	0	14	14	0	4	4	0	2	2	0	60	60	0	8.28	0
Corpus uteri	0	0	0	0	5	5	0	18	18	0	66	66	0	104	104	0	70	70	0	16	16	0	279	279	0	35.62	0
Uterus, NOS	0	0	0	0	0	0	0	0	0	0	2	2	0	2	2	0	0	0	0	0	0	0	4	4	0	0.56	0
Ovary	0	2	2	0	9	9	0	10	10	0	20	20	0	28	28	0	15	15	0	9	9	0	93	93	0	12.25	0
Other female genital system	0	1	1	0	0	0	0	4	4	0	5	5	0	13	13	0	16	16	0	7	7	0	46	46	0	5.64	0

Note:

- ASIR: Age-standardized Incidence Rates using the 2011 Manitoba Standard Population
- Rates are per 100,000 persons
- CLL/SLL: Chronic lymphocytic leukemia/Small lymphocytic lymphoma

Table A.4. Cancer Incidence - New Case Counts and ASIRs by Sex, Age Group, and Cancer Type, standardized using the 2011 Manitoba standard population (Contd.)

CANCER TYPE	AGE GROUP																					TOTAL			ASIR		
	00-29			30-39			40-49			50-59			60-69			70-79			80+								
	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T
Prostate	0	0	0	0	0	0	7	0	7	103	0	103	365	0	365	369	0	369	141	0	141	985	0	985	130.96	0	0
Testis	11	0	11	9	0	9	6	0	6	1	0	1	1	0	1	1	0	1	1	0	1	30	0	30	4.34	0	0
Penis	0	0	0	1	0	1	0	0	0	1	0	1	0	0	0	3	0	3	3	0	3	8	0	8	1.20	0	0
Other male genital system	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	1	1	0	1	3	0	3	0.42	0	0
Bladder	0	0	0	0	2	2	6	3	9	8	0	8	27	10	37	49	10	59	38	15	53	128	40	168	18.28	4.77	10.82
Kidney	2	0	2	6	4	10	12	7	19	40	8	48	52	24	76	36	23	59	21	8	29	169	74	243	23.79	9.12	16.08
Ureter	0	0	0	0	0	0	0	0	0	0	0	3	1	4	2	0	2	1	1	2	6	2	8	0.78	0.24	0.49	
Other urinary system	0	0	0	0	0	0	0	0	0	0	0	3	2	5	0	0	0	3	0	3	6	2	8	0.92	0.24	0.52	
Eye	1	0	1	0	0	0	1	0	1	0	1	1	0	1	1	1	2	6	0	6	10	2	12	1.66	0.26	0.84	
Brain	9	10	19	1	2	3	4	3	7	10	4	14	16	4	20	12	11	23	2	3	5	54	37	91	7.40	4.90	6.13
Other nervous system	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Thyroid	0	11	11	9	18	27	5	27	32	17	21	38	13	21	34	8	14	22	3	2	5	55	114	169	7.77	15.92	11.81
Other endocrine	1	2	3	2	2	4	2	0	2	2	3	5	3	2	5	3	3	6	0	0	0	13	12	25	1.76	1.60	1.68
Hodgkin lymphoma	8	8	16	5	4	9	1	2	3	4	2	6	2	2	4	2	1	3	1	0	1	23	19	42	3.29	2.73	2.99
Non-Hodgkin lymphoma	5	2	7	3	4	7	9	5	14	25	19	44	45	41	86	50	40	90	41	26	67	178	137	315	25.45	16.81	20.61
Multiple myeloma	0	0	0	0	0	0	1	0	1	9	3	12	19	16	35	23	10	33	6	7	13	58	36	94	7.70	4.25	5.90
Acute lymphocytic leukemia	5	3	8	0	0	0	0	0	0	1	3	4	1	0	1	0	1	1	0	0	0	7	7	14	1.01	1.05	1.04
CLL/SLL	0	0	0	0	0	0	2	3	5	5	6	11	21	5	26	10	9	19	7	5	12	45	28	73	6.12	3.57	4.76
Acute myeloid leukemia	6	4	10	1	1	2	1	2	3	1	2	3	10	8	18	13	7	20	9	7	16	41	31	72	5.73	3.90	4.71
Chronic myeloid leukemia	0	0	0	1	0	1	2	2	4	1	1	2	0	1	1	2	1	3	2	1	3	8	6	14	1.22	0.82	0.99
Other leukemias	0	0	0	1	0	1	1	0	1	1	1	2	2	0	2	2	1	3	2	1	3	9	3	12	1.30	0.38	0.81
Other ill-defined & unknown	0	2	2	2	3	5	4	3	7	12	7	19	30	16	46	33	29	62	40	32	72	121	92	213	17.72	11.06	13.98
TOTAL - INVASIVE	59	70	129	70	131	201	133	268	401	490	525	1015	1132	967	2099	1214	953	2167	657	638	1295	3755	3552	7307	518.05	445.23	475.44
Non-Melanoma skin	4	4	8	20	25	45	53	82	135	170	153	323	381	313	694	531	356	887	363	347	710	1522	1280	2802	214.32	157.35	182.33
In situ skin	2	1	3	7	6	13	10	19	29	22	34	56	91	78	169	147	115	262	115	108	223	394	361	755	55.84	43.61	48.67
Breast in situ	0	0	0	0	1	1	0	10	10	0	40	40	0	45	45	0	30	30	0	6	6	0	132	132	0	17.31	8.85
Cervix in situ	0	154	154	0	200	200	0	70	70	0	32	32	0	21	21	0	4	4	0	0	0	0	481	481	0	69.02	0
Prostate in situ	0	0	0	0	0	0	1	0	1	2	0	2	7	0	7	6	0	6	1	0	1	17	0	17	2.21	0	0
Bladder in situ	0	0	0	1	0	1	4	1	5	18	4	22	31	12	43	52	13	65	35	9	44	141	39	180	19.97	4.65	11.59
Other in situ (Excl. Breast, Skin, Cervix, Prostate)	1	3	4	0	7	7	1	14	15	3	17	20	18	20	38	16	23	39	6	9	15	45	93	138	5.94	12.19	9.07
TOTAL - INVASIVE + IN SITU	66	232	298	98	370	468	202	464	666	705	805	1510	1660	1456	3116	1966	1494	3460	1177	1117	2294	5874	5938	11812	816.33	749.37	771.33
Brain uncertain & unspecified	0	2	2	2	3	5	1	0	1	0	1	1	3	0	3	2	2	4	1	0	1	9	8	17	1.20	1.07	1.11
Neoplasms (Uncertain & unspecified excl. brain)	14	13	27	5	16	21	9	16	25	13	21	34	31	31	62	39	30	69	26	20	46	137	147	284	19.36	19.21	18.99
Brain & nervous system benign	0	6	6	3	3	6	1	8	9	7	11	18	9	13	22	8	5	13	9	18	27	37	64	101	5.37	8.58	7.01
ALL CANCERS	80	253	333	108	392	500	213	488	701	725	838	1563	1703	1500	3203	2015	1531	3546	1213	1155	2368	6057	6157	12214	842.26	778.24	798.43

Note:

- ASIR: Age-standardized Incidence Rates using the 2011 Manitoba Standard Population
- Rates are per 100,000 persons
- CLL/SLL: Chronic lymphocytic leukemia/Small lymphocytic lymphoma

Table A.5. Cancer Incidence - New Case Counts and ASIRs by Sex and Cancer Type, standardized using the 2011 Manitoba and Canada population, and the 2000-2025 W.H.O Standard Population

CANCER TYPE	MALE				FEMALE				TOTAL			
	CASES	ASIR ¹	ASIR ²	ASIR ³	CASES	ASIR ¹	ASIR ²	ASIR ³	CASES	ASIR ¹	ASIR ²	ASIR ³
Lip	41	5.57	5.8	3.43	18	2.23	2.25	1.26	59	3.8	3.93	2.30
Tongue	49	6.8	7.12	4.57	8	1.06	1.12	0.74	57	3.78	3.98	2.59
Major salivary gland	5	0.71	0.74	0.43	13	1.71	1.82	1.25	18	1.21	1.28	0.84
Floor of mouth	6	0.76	0.82	0.52	7	0.84	0.91	0.58	13	0.8	0.86	0.55
Gum & other mouth	17	2.34	2.41	1.43	5	0.57	0.56	0.27	22	1.4	1.43	0.83
Nasopharynx	1	0.12	0.13	0.08	2	0.22	0.24	0.15	3	0.17	0.19	0.12
Oropharynx	11	1.61	1.67	1.03	2	0.28	0.3	0.20	13	0.9	0.94	0.60
Hypopharynx	5	0.59	0.64	0.40	2	0.24	0.24	0.13	7	0.42	0.44	0.26
Other buccal cavity & pharynx	35	4.83	5.15	3.50	4	0.5	0.54	0.35	39	2.62	2.80	1.90
Esophagus	62	8.39	8.87	5.61	20	2.31	2.34	1.27	82	5.28	5.54	3.40
Stomach	100	13.96	14.39	8.28	48	5.8	5.98	3.55	148	9.51	9.83	5.75
Small intestine	28	3.92	4.11	2.55	21	2.38	2.45	1.36	49	3.16	3.28	1.95
Colorectal	499	69.94	72.49	44.34	404	49.54	51.27	31.46	903	59.05	61.22	37.60
Colon excluding rectum	301	42.43	43.67	26.12	290	35.14	36.13	21.57	591	38.49	39.62	23.71
Rectum & rectosigmoid	198	27.51	28.82	18.23	114	14.4	15.15	9.89	312	20.56	21.60	13.89
Anus	9	1.19	1.28	0.83	27	3.43	3.54	2.14	36	2.42	2.52	1.53
Liver	50	6.54	6.93	4.43	32	3.86	4.08	2.51	82	5.16	5.46	3.45
Gallbladder	11	1.37	1.45	0.87	17	2.02	2.1	1.26	28	1.72	1.80	1.07
Pancreas	123	16.81	17.54	10.65	81	9.8	10.04	5.71	204	13.16	13.64	8.09
Other digestive system	42	5.93	6.14	3.60	45	5.26	5.36	3.21	87	5.62	5.77	3.41
Larynx	27	3.64	3.84	2.41	6	0.75	0.79	0.51	33	2.13	2.26	1.43
Lung & bronchus	434	59.4	61.6	36.03	476	56.63	58.95	35.02	910	57.69	59.96	35.38
Other respiratory system	14	2.16	2.15	1.43	5	0.66	0.68	0.57	19	1.32	1.33	0.97
Bones & joints	2	0.24	0.26	0.17	8	1.09	1.1	1.09	10	0.66	0.68	0.62
Soft tissue (Including heart)	28	4.03	4.13	2.81	33	4.41	4.54	3.51	61	4.14	4.26	3.13
Kaposi sarcoma	2	0.31	0.3	0.15	1	0.16	0.17	0.12	3	0.21	0.22	0.13
Mesothelioma	19	2.95	2.91	1.55	4	0.49	0.51	0.30	23	1.54	1.54	0.85
Melanoma of the skin	175	24.58	25.46	15.75	140	17.45	18.25	12.18	315	20.61	21.47	13.80
Breast	3	0.53	0.51	0.25	999	127.54	134.35	89.52	1002	66.7	70.04	46.14
Cervix uteri	n/a	n/a	n/a	n/a	60	8.28	8.69	7	60	8.28	n/a	n/a
Corpus uteri	n/a	n/a	n/a	n/a	279	35.62	38.04	25	279	35.62	n/a	n/a
Uterus, NOS	n/a	n/a	n/a	n/a	4	0.56	0.6	0	4	0.56	n/a	n/a
Ovary	n/a	n/a	n/a	n/a	93	12.25	12.91	9	93	12.25	n/a	n/a
Other female genital system	n/a	n/a	n/a	n/a	46	5.64	5.93	4	46	5.64	n/a	n/a
Prostate	985	130.96	137.44	81.90	n/a	n/a	n/a	n/a	985	130.96	n/a	n/a
Testis	30	4.34	4.34	4.62	n/a	n/a	n/a	n/a	30	4.34	n/a	n/a
Penis	8	1.2	1.2	0.70	n/a	n/a	n/a	n/a	8	1.2	n/a	n/a
Other male genital system	3	0.42	0.43	0.23	n/a	n/a	n/a	n/a	3	0.42	n/a	n/a
Bladder	128	18.28	18.62	10.45	40	4.77	4.86	2.91	168	10.82	11.06	6.38
Kidney	169	23.79	24.92	16.22	74	9.12	9.66	6.46	243	16.08	16.93	11.19
Ureter	6	0.78	0.82	0.48	2	0.24	0.24	0.13	8	0.49	0.51	0.29
Other urinary system	6	0.92	0.91	0.45	2	0.24	0.26	0.16	8	0.52	0.53	0.29
Eye	10	1.66	1.59	0.90	2	0.26	0.28	0.18	12	0.84	0.83	0.50
Brain	54	7.4	7.69	5.98	37	4.9	4.96	4.38	91	6.13	6.31	5.16
Other nervous system	0	0	0	0	0	0	0	0	0	0	0	0
Thyroid	55	7.77	8.22	5.96	114	15.92	16.69	13.97	169	11.81	12.43	9.94
Other endocrine	13	1.76	1.86	1.49	12	1.6	1.66	1.41	25	1.68	1.76	1.45
Hodgkin lymphoma	23	3.29	3.3	3.25	19	2.73	2.73	2.92	42	2.99	2.99	3.07
Non-Hodgkin lymphoma	178	25.45	26.12	16.02	137	16.81	17.58	11.20	315	20.61	21.36	13.41
Multiple myeloma	58	7.7	8.13	4.98	36	4.25	4.47	2.66	94	5.9	6.22	3.78
Acute lymphocytic leukemia	7	1.01	0.98	1.13	7	1.05	1.05	1.00	14	1.04	1.02	1.07
Chronic lymphocytic leukemia/Small lymphocytic lymphoma	45	6.12	6.41	3.88	28	3.57	3.75	2.38	73	4.76	4.99	3.09
Acute myeloid leukemia	41	5.73	5.78	3.99	31	3.9	3.98	2.90	72	4.71	4.77	3.40
Chronic myeloid leukemia	8	1.22	1.24	0.85	6	0.82	0.86	0.60	14	0.99	1.02	0.71
Other leukemias	9	1.3	1.34	0.87	3	0.38	0.39	0.23	12	0.81	0.83	0.54
Other ill-defined & unknown	121	17.72	17.95	10.06	92	11.06	11.26	6.82	213	13.98	14.22	8.27
TOTAL – INVASIVE	3755	518.05	538.14	331.56	3552	445.23	465.34	306.46	7307	475.44	495.80	638.03
Non-Melanoma skin	1522	214.32	220.48	129.00	1280	157.35	162.84	99.75	2802	182.33	188.30	112.86
<i>In situ</i> Skin	394	55.84	56.87	32.30	361	43.61	44.94	26.91	755	48.67	49.91	29.17
Breast <i>in situ</i>	0	0	0	0	132	17.31	18.5	12	132	8.85	9.45	6.24
Cervix <i>in situ</i>	0	0	0	0	481	69.02	69.47	76	481	69.02	0	0
Prostate <i>in situ</i>	17	2.21	2.36	1.50	0	0	0	0.00	17	2.21	0	0
Bladder <i>in situ</i>	141	19.97	20.51	11.83	39	4.65	4.86	2.89	180	11.59	11.99	7.05
Other <i>in situ</i> (Excl. Breast, Skin, Cervix, Prostate, Bladder)	45	5.94	6.23	3.84	93	12.19	12.82	9.26	138	9.07	9.54	6.56

TOTAL - INVASIVE + <i>IN SITU</i>	5874	816.33	844.58	510	5938	749.37	778.76	533	11812	771.33	800.70	517
Brain uncertain & unspecified	9	1.2	1.26	0.92	8	1.07	1.09	1.09	17	1.11	1.15	1.00
Neoplasms (Uncertain & unspecified, excluding brain)	137	19.36	19.76	13.57	147	19.21	19.9	15.19	284	18.99	19.55	14.26
Brain & nervous system benign	37	5.37	5.51	3.39	64	8.58	8.73	6.26	101	7.01	7.14	4.82
ALL CANCERS	6057	842.26	871.12	527.92	6157	778.24	808.48	555.97	12214	798.43	828.54	536.69

Note:

- ASIR¹: Age-standardized Incidence Rates using the 2011 Manitoba Standard Population; ASIR²: Age-standardized Incidence Rates using the 2011 Canada Standard Population; ASIR³: Age-standardized Incidence rates using the 2000-2025 W.H.O Standard Population
- Rates are per 100,000 persons
- n/a: Not Applicable

6.4 Glossary and Definitions

Counts

Incidence counts are the number of new cancer cases diagnosed in a population during a specific period. In this report, incidence counts refer to the number of new cancers diagnosed in Manitoba during the 2021 calendar year.

Mortality counts describe the number of deaths attributed to cancer during a specific period in a specific population. In this report, mortality refers to the number of deaths in Manitoba, during the 2021 calendar year, that are due to cancer.

Rates

Incidence and mortality rates are the number of new cancer cases or deaths per 100,000 people in a population during a specific period. Rates presented by sex are per 100,000 males or 100,000 females in the population during the specified period. The rates are sometimes called crude rates because they do not adjust for the age distribution of the population.

Age-Specific Rates

An age-specific rate is the incidence or mortality rate for a specified age group. Age-specific rate is calculated by dividing the total number of new cancer cases or deaths for the specific age group of interest (numerator) by the total population in that same age group (denominator); it is expressed as the number of new cancer cases or deaths per 100,000 population at risk.

Age-Standardized Rates

Age-standardized rates are weighted averages of age-specific rates using a standard population that allow comparisons of cancer rates between populations with different age structures. They give the hypothetical rate that would have occurred if the population had the same age distribution as the standard population. In this report, age-standardized rates are calculated using the direct method to the 2011 Manitoba standard population.

Cancer incidence

The number of new cancer cases diagnosed during a specific period in a population.

Cancer mortality

The number of deaths from cancer during a specific period in a population.

International Classification of Diseases for Oncology (ICD-o)

An international standard for classifying cancer using a topographical code, which describes the anatomical site of origin (or organ system) of the tumour, and a morphological code, which describes the cell type (or histology) of the tumour and the behaviour (malignant or benign).

International Classification of Diseases, Tenth Revision (ICD-10)

The tenth revision of the International Classification of Diseases (ICD) which is a standard designed to promote international comparability in the collection, processing, classification, and presentation of mortality statistics. This includes providing a format for reporting causes of death on the death certificate.

Most common cancers

In this report, the 4 most commonly diagnosed cancers in Manitoba are breast, prostate, lung, and colorectal.

Primary cancer

The original, or first, tumour in the body. Cancer cells from primary cancer may spread to other body parts and form new, or secondary, tumours.

Stage at diagnosis

Refers to how much a cancer has spread at the time of diagnosis.

Standard population

The age distribution used as weights to create age-standardized (i.e., age-adjusted) statistics.

6.5 Cancer Site Grouping ICD-O3

The Manitoba Cancer Registry uses disease site groupings according to the International Classification of Diseases for Oncology Third Edition (ICD-O3), based on Surveillance Epidemiology and End Results (SEER) Groups. The primary site groupings used for incidence are shown in Table A.2.

Table A.2. Primary Cancer Site Groupings for Incidence

PRIMARY SITE	SITE/CELL TYPE	EXCLUDE TYPES:
Buccal cavity and pharynx	C00:C14	9590:9993
Lip	C000:C009	9590:9993
Tongue	C019:C029	9590:9993
Major salivary gland	C079:C089	9590:9993
Floor of mouth	C040:C049	9590:9993
Gum & other mouth	C030:C039, C050:C059, C060:C069	9590:9993
Nasopharynx	C110:C119	9590:9993
Oropharynx	C100:C109	9590:9993
Hypopharynx	C129, C130:C139	9590:9993
Other buccal cavity & pharynx	C090:C099, C140, C142:C148	9590:9993
Digestive system	C15:C26	9590:9993
Esophagus	C150:C159	9590:9993
Stomach	C160:C169	9590:9993
Small intestine	C170:C179	9590:9993
Colon excluding rectum	C180:C189, C260	9590:9993
Rectum & Rectosigmoid	C199, C209	9590:9993
Anus	C210:C212, C218	9590:9993
Liver	C220	9590:9993
Gallbladder	C239	9590:9993
Pancreas	C250:C259	9590:9993
Other digestive system	C240:C249, C221, C480, C481:C482, C268:C269, C488	9590:9993
Respiratory system	C30:C39	9590:9993
Larynx	C320:C329	9590:9993
Lung & bronchus	C340:C349	9590:9993
Other respiratory system	C300:C301, C310:C319, C384, C339, C381:C383, C388, C390:C399	9590:9993
Bones & joints	C400:C419	9590:9993
Soft tissue (including heart)	C380, C470:C479, C490:C499	9590:9993
Mesothelioma	types 9050:9055	
Kaposi sarcoma	types 9140	
Skin	C44	9590:9993
Melanomas of the skin	C440:C449 (types 8720:8790)	9590:9993

Other skin	C440:C449	9590:9993
Breast	C500:C509	9590:9993
Female genital system	C51:C58	9590:9993
Cervix uteri	C530:C539	9590:9993
Corpus uteri	C540:C549	9590:9993
Uterus, NOS	C559	9590:9993
Ovary	C569	9590:9993
Other female genital system	C529, C510:C519, C570:C589	9590:9993
Male genital system	C60:C63	9590:9993
Prostate	C619	9590:9993
Testis	C620:C629	9590:9993
Penis	C600:C609	9590:9993
Other male genital system	C630:C639	9590:9993
Urinary system	C64:C68	9590:9993
Bladder (incl. in situ)	C670:C679	9590:9993
Kidney and renal pelvis	C649, C659	9590:9993
Ureter	C669	9590:9993
Other urinary system	C680:C689	9590:9993
Eye	C690:C699	9590:9993
Brain & other nervous system	C70:C72	9590:9993
Brain	C710:C719	9590:9993
Other nervous system	C710:C719 (type 953), C700:C709 C720:C729	9590:9993 9590:9993
Endocrine	C73:C75	9590:9993
Thyroid	C739	9590:9993
Other endocrine	C379, C740:C749, C750:C759	9590:9993
Lymphomas	C77	
Hodgkin disease	types 9650-9653, 9655, 9659, 9663	
Non-Hodgkin lymphoma	types 9590:9597, 9671:9719, 9727, 9766, 9819 type 9687, all sites except C420, C421, C424 type 9811, all sites except C420, C421, C424 type 9827, all sites except C420, C421, C424 type 9837, all sites except C420, C421, C424	
Multiple myeloma	types 9731, 9732, 9734, site C421	
Leukemias	C42	
Acute lymphocytic	type 9835 type 9687, sites C420, C421, C424 type 9837, sites C420, C421, C424 types 9811-9818, sites C420, C421, C424	
Chronic lymphocytic leukemia/Small lymphocytic lymphoma	type 9823	
Acute myeloid	types 9840, 9861, 9865, 9866, 9867, 9869, 9870:9874, 9877:9879, 9891, 9895:9898, 9910:9912, 9920, 9930:9931, 9987	
Chronic myeloid	types 9863, 9875, 9876, 9945, 9946	
Other	types 9733, 9742, 9800, 9801, 9805, 9806:9809, 9820, 9831, 9832:9834, 9860, 9940, 9948, 9963, 9964 type 9827, sites C420, C421, C424	
Other, ill-defined, & unknown	types 9740, 9741, 9749, 9750:9758, 9760:9769, 9950:9962, 9968, 9970:9993 C760:C768 C809 C420:C424 C770:C779	9050:9055, 9140, 9590:9993 9050:9055, 9140, 9590:9993 9050:9055, 9140, 9590:9993 9050:9055, 9140, 9590:9993

6.6. Citation and Referencing

TO CITE THIS REPORT: Department of Epidemiology and Cancer Registry, CancerCare Manitoba. “Cancer in Manitoba, 2021 Annual Statistical Report.”

Find the Department of Epidemiology and Cancer Registry and data request guidelines online under the Research tab at www.cancercare.mb.ca

CONTACT DETAILS

Epidemiology and Cancer Registry

CancerCare Manitoba

675 McDermot Ave.

Winnipeg, MB R3E 0V9

Telephone: (204) 787-2174

Email: CCMBepireg@cancercare.mb.ca